Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Perspective on Takeda/Shire Deal - 3: Takeda Shareholders Got Short End of the Stick
Takeda shareholders got the short end of the stick with the Shire deal, says ex-analyst Shigeru Mishima, criticizing the acquisition. Mr Mishima, now president of market research firm Pharma Asset Research, acts as a spokesman for a group made…
To read the full story
Related Article
BUSINESS
- Nxera’s Partner Earns Taiwan Approval for Daridorexant
April 15, 2026
- Daiichi Sankyo’s I-DXd Filed in US for SCLC, Wins Priority Review
April 15, 2026
- Sanofi Japan Sales Rise 4.5% in 2025 as Dupixent Widens Label
April 15, 2026
- Eylea Biosimilar Supply Curbed amid Originator Disruption
April 14, 2026
- Novartis, JSH Begin Project to Address Regional Gaps in Hematology Care
April 14, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…